MCQ SLE
1 / 20
Which of the following is a common side effect of abatacept therapy?
Incorrect!
Upper respiratory tract infections are common side effects of abatacept therapy.
Correct!
2 / 20
Which of the following medications is a Bruton's tyrosine kinase (BTK) inhibitor that has shown efficacy in the treatment of SLE?
Ibrutinib is a BTK inhibitor that has shown efficacy in the treatment of SLE, particularly in patients with refractory disease.
RuxolitinibRuxolitinib is a Janus kinase (JAK) inhibitor primarily used in myeloproliferative neoplasms like myelofibrosis and polycythemia vera but is not specifically indicated for SLE treatment.
FedratinibFedratinib is another JAK inhibitor approved for myelofibrosis but is not indicated for SLE treatment.
DasatinibDasatinib is a tyrosine kinase inhibitor used in certain leukemias and is not indicated for SLE treatment or known to target BTK.
3 / 20
Which of the following medications is a targeted biologic therapy approved for the treatment of SLE?
MethotrexateMethotrexate is an immunosuppressive medication used in various autoimmune diseases, including rheumatoid arthritis and psoriasis, but it is not specifically a targeted biologic therapy for SLE.
AzathioprineAzathioprine is an immunosuppressive medication used in SLE, particularly for systemic disease activity and organ involvement, but it is not a targeted biologic therapy like belimumab.
Mycophenolate mofetilMycophenolate mofetil is another immunosuppressive medication used in SLE, particularly for managing renal involvement and systemic disease activity, but it is not a targeted biologic therapy like belimumab.
Belimumab is a monoclonal antibody that targets B-cell activating factor (BAFF) and is approved for the treatment of SLE.
4 / 20
Which of the following medications is an interleukin-6 (IL-6) receptor antagonist used in the treatment of SLE?
AbataceptAbatacept is a T cell co-stimulation blocker used in autoimmune diseases like rheumatoid arthritis and psoriatic arthritis but is not specifically indicated for SLE treatment.
AnakinraAnakinra is an interleukin-1 (IL-1) receptor antagonist used in diseases like rheumatoid arthritis and cryopyrin-associated periodic syndromes (CAPS) but is not typically used in SLE treatment.
SecukinumabSecukinumab is an interleukin-17A (IL-17A) inhibitor used in diseases like psoriasis, psoriatic arthritis, and ankylosing spondylitis but is not indicated for SLE treatment.
Tocilizumab is an IL-6 receptor antagonist that has shown efficacy in the treatment of SLE.
5 / 20
Which of the following medications is a complement inhibitor approved for the treatment of SLE?
RituximabRituximab is a monoclonal antibody that targets CD20-positive B cells and is used in various autoimmune diseases, but it is not specifically a complement inhibitor and is not approved for SLE treatment based on complement inhibition.
TocilizumabTocilizumab is an interleukin-6 (IL-6) receptor antagonist used in autoimmune diseases like rheumatoid arthritis and giant cell arteritis but is not a complement inhibitor and is not approved for SLE treatment based on complement inhibition.
AbataceptAbatacept is a T cell co-stimulation blocker used in autoimmune diseases like rheumatoid arthritis and psoriatic arthritis but is not a complement inhibitor and is not approved for SLE treatment based on complement inhibition.
Eculizumab is a complement inhibitor that has shown efficacy in the treatment of SLE, particularly in patients with refractory disease.
6 / 20
Which of the following is a common laboratory finding in SLE?
ThrombocytosisThrombocytosis refers to an elevated platelet count, which is not a common laboratory finding in SLE. Thrombocytopenia, or a low platelet count, is actually more typical in SLE.
LeukocytosisLeukocytosis refers to an elevated white blood cell count, which can occur in infections or inflammatory conditions but is not specifically a common finding in SLE.
HyperkalemiaHyperkalemia, or high potassium levels in the blood, is not typically a common laboratory finding in SLE unless there is associated kidney dysfunction or certain medication effects.
Anemia, or low red blood cell count, is a common laboratory finding in SLE.
7 / 20
Which of the following medications is a sphingosine-1-phosphate receptor modulator that has shown efficacy in the treatment of SLE?
OzanimodOzanimod is another sphingosine-1-phosphate receptor modulator used in multiple sclerosis but is not specifically indicated for SLE treatment.
Siponimod Siponimod is also a sphingosine-1-phosphate receptor modulator used in multiple sclerosis but is not indicated for SLE treatment.
Ponesimod Ponesimod is a selective sphingosine-1-phosphate receptor modulator used in multiple sclerosis but is not indicated for SLE treatment.
Fingolimod is a sphingosine-1-phosphate receptor modulator that has shown efficacy in the treatment of SLE.
8 / 20
Which of the following is a common treatment for skin manifestations of SLE?
NSAIDsNonsteroidal anti-inflammatory drugs (NSAIDs) are mainly used for managing pain and inflammation in joints and muscles in SLE, but they are not typically used as a primary treatment for skin manifestations.
HydroxychloroquineHydroxychloroquine is a cornerstone medication in the management of SLE, particularly for systemic symptoms and to prevent disease flares. While it can have beneficial effects on some skin manifestations, it is not specifically a treatment for acute or localized skin lesions.
AzathioprineAzathioprine is an immunosuppressive medication used in SLE to manage systemic disease activity and organ involvement. It is not typically used as a first-line treatment for skin manifestations but may be considered in cases of refractory or severe skin involvement.
Topical corticosteroids are commonly used to treat skin manifestations of SLE.
9 / 20
Which of the following is a common side effect of rituximab therapy?
Infusion reactions, such as fever, chills, and rash, can occur with rituximab therapy.
10 / 20
Which of the following is a common treatment for arthritis in SLE?
MethotrexateMethotrexate is an immunosuppressive medication used in various autoimmune diseases, including rheumatoid arthritis, but it is not typically a first-line treatment for arthritis in SLE.
AzathioprineAzathioprine is another immunosuppressive medication used in SLE, mainly for systemic disease activity and organ involvement. While it may have some effects on arthritis, it is not specifically a primary treatment for arthritis in SLE.
Mycophenolate mofetilMycophenolate mofetil is an immunosuppressive agent used in SLE, particularly for managing renal involvement and systemic disease activity. It may have some benefits for arthritis, but it is not typically used as a first-line treatment for arthritis in SLE.
Hydroxychloroquine is a common treatment for arthritis in systemic lupus erythematosus (SLE). It is an antimalarial medication that has immunomodulatory effects and is often used to manage joint pain, inflammation, and stiffness in SLE patients with arthritis.
11 / 20
Which of the following medications is a monoclonal antibody that targets the CD20 antigen on B cells and has shown efficacy in the treatment of SLE?
AbataceptAbatacept is a T cell co-stimulation blocker used in autoimmune diseases like rheumatoid arthritis but does not target B cells and is not specifically indicated for SLE treatment.
TocilizumabTocilizumab is an interleukin-6 (IL-6) receptor antagonist used in autoimmune diseases like rheumatoid arthritis and giant cell arteritis but is not a monoclonal antibody targeting B cells and is not specifically indicated for SLE treatment.
SecukinumabSecukinumab is an interleukin-17A (IL-17A) inhibitor used in conditions like psoriasis and ankylosing spondylitis but is not a B cell-targeted therapy and is not indicated for
Rituximab is a monoclonal antibody that targets the CD20 antigen on B cells and has shown efficacy in the treatment of SLE.
12 / 20
Which of the following medications is used for the treatment of lupus nephritis?
RituximabRituximab is a monoclonal antibody that targets B cells and is used in various autoimmune diseases. While it may have a role in certain refractory cases of lupus nephritis, it is not typically considered a first-line treatment.
BelimumabBelimumab is a monoclonal antibody that inhibits B cell activation and is approved for the treatment of SLE. However, its primary indication is for systemic disease activity, and it is not specifically targeted at lupus nephritis.
Tocilizumab
Tocilizumab is a monoclonal antibody that blocks interleukin-6 (IL-6) and is used in conditions like rheumatoid arthritis. It is not a standard treatment for lupus nephritis.
Correct!Cyclophosphamide is commonly used for the treatment of lupus nephritis, especially in severe cases.
13 / 20
Which of the following is a common side effect of belimumab therapy?
HepatotoxicityHepatotoxicity, or liver damage, is not a common side effect of belimumab therapy.
NephrotoxicityNephrotoxicity, or kidney damage, is not a common side effect of belimumab therapy.
HypertensionHypertension, or high blood pressure, is not commonly associated with belimumab therapy as a specific side effect. However, patients with SLE may have hypertension due to the underlying disease process or other medications used to manage SLE-related complications.
Infusion reactions, such as fever, chills, and rash, can occur with belimumab therapy.
14 / 20
Which of the following medications is considered a first-line treatment for mild to moderate SLE?
MethotrexateMethotrexate is an immunosuppressive medication used in various autoimmune diseases, including rheumatoid arthritis and psoriasis, but it is not typically considered a first-line treatment for SLE unless there is specific joint involvement that is not adequately controlled by hydroxychloroquine.
CyclophosphamideCyclophosphamide is a potent immunosuppressive medication used in severe forms of SLE with organ involvement, such as lupus nephritis or central nervous system manifestations. It is not typically used as a first-line treatment for mild to moderate SLE.
Mycophenolate mofetilMycophenolate mofetil is an immunosuppressive medication used in SLE, particularly for managing renal involvement and systemic disease activity. It may be considered as a second-line or adjunctive treatment in moderate to severe SLE cases but is not usually a first-line treatment for mild to moderate SLE.
Hydroxychloroquine is considered a first-line treatment for mild to moderate SLE due to its efficacy and safety profile.
15 / 20
Which of the following medications is a selective T cell co-stimulation modulator that has shown efficacy in the treatment of SLE?
AnakinraAnakinra is an interleukin-1 (IL-1) receptor antagonist used in conditions like rheumatoid arthritis and autoinflammatory disorders but is not specifically indicated for SLE treatment.
TocilizumabTocilizumab is an interleukin-6 (IL-6) receptor antagonist used in conditions like rheumatoid arthritis and giant cell arteritis but is not a selective T cell co-stimulation modulator and is not specifically indicated for SLE treatment.
SecukinumabSecukinumab is an interleukin-17A (IL-17A) inhibitor used in conditions like psoriasis and ankylosing spondylitis but is not a selective T cell co-stimulation modulator and is not indicated for SLE treatment.
Abatacept is a selective T cell co-stimulation modulator that has shown efficacy in the treatment of SLE.
16 / 20
Which of the following medications is a Janus kinase (JAK) inhibitor used in the treatment of SLE?
AdalimumabAdalimumab is a tumor necrosis factor-alpha (TNF-alpha) inhibitor used in various autoimmune diseases, but it is not a JAK inhibitor and is not specifically approved for SLE treatment.
EtanerceptEtanercept is another TNF-alpha inhibitor used in autoimmune diseases like rheumatoid arthritis, psoriasis, and ankylosing spondylitis. It is not a JAK inhibitor and is not approved for SLE treatment.
InfliximabInfliximab is a TNF-alpha inhibitor used in autoimmune diseases such as rheumatoid arthritis, Crohn's disease, and psoriasis. Like etanercept and adalimumab, it is not a JAK inhibitor and is not indicated for SLE treatment.
Tofacitinib is a JAK inhibitor that has shown promise in the treatment of SLE.
17 / 20
Which of the following is a common side effect of hydroxychloroquine therapy in SLE?
NephrotoxicityNephrotoxicity refers to kidney damage caused by certain medications or toxins. It is not a common side effect of hydroxychloroquine therapy in SLE.
HepatotoxicityHepatotoxicity refers to liver damage caused by medications or other factors. While hydroxychloroquine can rarely cause liver-related side effects, hepatotoxicity is not a common side effect of hydroxychloroquine therapy in SLE.
Myelosuppression Myelosuppression refers to suppression of bone marrow function leading to decreased production of blood cells. It is not typically associated with hydroxychloroquine therapy in SLE.
Retinopathy is a potential side effect of long-term hydroxychloroquine therapy in SLE.
18 / 20
Which of the following is a common neuropsychiatric manifestation of SLE?
Peripheral neuropathyWhile peripheral neuropathy can occur in SLE, especially in patients with vasculitis or nerve involvement, it is not as common a neuropsychiatric manifestation as seizures.
MigraineMigraine headaches can occur in SLE patients, but they are not typically considered a neuropsychiatric manifestation unless they are severe or associated with other neurological symptoms.
ParkinsonismParkinsonism refers to symptoms resembling Parkinson's disease, such as tremors, rigidity, and bradykinesia. It is not a common neuropsychiatric manifestation of SLE.
Seizures can occur as a neuropsychiatric manifestation of SLE.
19 / 20
Which of the following medications is a proteasome inhibitor that has shown efficacy in the treatment of SLE?
LenalidomideLenalidomide is an immunomodulatory drug used in conditions like multiple myeloma, myelodysplastic syndromes, and certain lymphomas but is not specifically indicated for SLE treatment.
ThalidomideThalidomide is another immunomodulatory drug with various uses, including in multiple myeloma and erythema nodosum leprosum, but it is not a proteasome inhibitor and is not commonly used for SLE treatment.
PomalidomidePomalidomide is also an immunomodulatory drug primarily used in multiple myeloma and myelodysplastic syndromes but is not a proteasome inhibitor and is not indicated for SLE treatment.
Bortezomib is a proteasome inhibitor that has shown promise in the treatment of SLE, particularly in patients with skin manifestations.
20 / 20
Which of the following is a common side effect of eculizumab therapy?
Neutropenia, or low white blood cell count, can occur with eculizumab therapy.
Your score is
The average score is 55%
Restart quiz
This site uses cookies. Find out more about cookies and how you can refuse them.
Loading...
